| Name | Title | Contact Details |
|---|
Formed in 2019, through the merger of Sivantos and Widex, WS Audiology combines more than 140 years experience in pioneering the use of technology to help people with hearing loss hear the sounds that make life wonderful. Today, one out of three hearing aids is made by us and we are active in over 125 markets, employing close to 12,000 people worldwide. Our broad portfolio of leading hearing-related products and services generates annual revenues of more than € 2 billion. WS Audiology is privately owned by the Tøpholm and Westermann families, as well as funds under the management of EQT. As a global leader, our ambition is to unlock human potential by making wonderful sound part of everyone`s life.
Cannuflow Incorporated is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company`s first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO.
Prizm Medical is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.